Research on Colorectal Cancer Recurrence Monitoring and Individualized Treatment Based on MRD

This study aims to evaluate whether plasma molecular residual disease (MRD), assessed using circulating tumor DNA (ctDNA), can help optimize the duration of immunotherapy in patients with metastatic microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR) colorectal cancer. Patients with MSI-H/dMMR metastatic colorectal cancer can achieve durable responses to immune checkpoint inhibitors, but the optimal duration of treatment remains uncertain. Prolonged immunotherapy may increase treatment burden and the risk of immune-related adverse events. ctDNA-based MRD testing may pr

Trial Details

NCT ID
NCT07775950
Phase
NA
Sponsor
Sun Yat-sen University
Status
RECRUITING
Cancer Type
Colon Cancer Colorectal Cancer
Interventions
  • Discontinue NA Treatment
  • Continued Immunotherapy
  • Observation
Locations (sample)
  • Guangzhou, Guangdong, China|23.11667,113.25

Key Eligibility Criteria

  • Voluntary participation in the study and provision of written informed consent.
  • Age ≥18 years at the time of signing informed consent.
  • Histologically confirmed colorectal adenocarcinoma with mismatch repair deficiency (dMMR) or microsatellite instability-high (MSI-H) status.
  • Clinically confirmed stage IV disease.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Colon Cancer Colorectal Cancer Trials on Trialify →